ABSTRACT
Background: We aimed to examine concerns surrounding COVID-19 infection and healthcare access among South African young people (YP) living with HIV (YPLWH) and HIV-uninfected YP with the goal of identifying differences between groups. Methods: We examined cross-sectional data from the baseline procedures of the BUDDY study conducted among YP (13-24 years) living with and without HIV in Cape Town, South Africa from February-September 2021. YPLWH were recruited from an HIV clinic and HIV-uninfected YP were recruited through community outreach. Adjusted prevalence ratios (aPRs) were computed to estimate associations between HIV cohort and COVID-19 testing, vaccine acceptance, and access to healthcare services since March 2020 controlling for participant age and gender. Results: A total of 535 participants were enrolled into the study, including 217 YPLWH and 318 HIV-uninfected YP. The median age, 19.1 years (IQR=16.6-21.5), was similar between groups. YPLWH were 58% female and HIV-uninfected YP were 78% female (p<.001). YPLWH were less than half as likely than HIV-uninfected YP to have received a COVID-19 test (6% vs 12%, aPR=0.48, 95% CI 0.26-0.89), to be willing to accept a COVID-19 vaccine (49% vs 59%, aPR=0.84, 95% CI 0.71-0.99), and to be concerned about becoming severely ill from COVID-19 (60% vs 76%, aPR=0.79, 95% CI 0.69-0.89). Perceived risk of becoming infected with COVID-19 in the next month was similar between YPLWH and HIV-uninfected YP (32% vs 36%). YPLWH were more likely than HIV-uninfected YP to report being unable to attend a healthcare appointment (27% vs 20%, aPR=1.39, 95% CI 1.01-1.90). Further, a greater proportion of YPLWH attempted to access condoms (aPR=1.51, 95% CI 1.32-1.74) and HIV/STI testing services (aPR=1.58, 95% CI 1.38-1.80) than HIV-uninfected YP and, among females who attempted to access contraceptives services, YPLYW reported significantly lower access than HIV-uninfected YP (aPR=0.82, 95% CI 0.71-0.94) (Table 1). Last, among YPLWH, 28% reported missing an HIV care appointment, 14% reported running out of their HIV medication, and 34% reported they were worried about running out of their medication since March 2020. Conclusion: Experiences living with HIV may shape concerns around COVID-19 infection among YP. YPLWH reported greater health-seeking behavior than HIV-uninfected YP and a significant proportion reported missing an appointment and running out of their HIV medication. Services should devise strategies to prevent interruptions in healthcare access among YP.
ABSTRACT
Background. Accurate diagnosis and attribution of the aetiology of pneumonia are important for measuring the burden of disease, implementing appropriate treatment strategies and developing more effective interventions. Objectives. To produce revised guidelines for the diagnosis of pneumonia in South African (SA) children, encompassing clinical, radiological and aetiological methods. Methods. An expert group was established to review diagnostic evidence and make recommendations for a revised SA guideline. Published evidence was reviewed and graded using the British Thoracic Society grading system. Results. Diagnosis of pneumonia should be considered in a child with acute cough, fast breathing or difficulty breathing. Revised World Health Organization guidelines classify such children into: (i) severe pneumonia;(ii) pneumonia (tachypoea or lower chest indrawing);or (iii) no pneumonia. Malnourished or immunocompromised children with lower chest indrawing should be managed as cases of severe pneumonia. Pulse oximetry should be done, with hospital referral for oxygen saturation <92%. A chest X-ray is indicated in severe pneumonia or when tuberculosis (TB) is suspected. Microbiological investigations are recommended in hospitalised patients or in outbreak settings. Improved aetiological methods show the importance of co-infections. Blood cultures have a low sensitivity (<5%), for diagnosing bacterial pneumonia. Highly sensitive, multiplex tests on upper respiratory samples or sputum detect multiple potential pathogens in most children. However, even in symptomatic children, it may be impossible to distinguish colonising from causative organisms, unless identification of the organism is strongly associated with attribution to causality, e.g. respiratory syncytial virus, Mycobacterium tuberculosis, Bordetella pertussis, influenza, para-influenza or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Investigations for TB should be considered in children with severe pneumonia who have been hospitalised, in a case of a known TB contact, if the tuberculin skin test is positive, if a child is malnourished or has lost weight, and in children living with HIV. Induced sputum may provide a higher yield than upper respiratory sampling for B. pertussis, M. tuberculosis and Pneumocystis jirovecii. Conclusions. Advances in clinical, radiological and aetiological methods have improved the diagnosis of childhood pneumonia.
ABSTRACT
BACKGROUND. More comprehensive immunisation regimens, strengthening of HIV prevention and management programmes and improved socioeconomic conditions have impacted on the epidemiology of paediatric community-acquired pneumonia (CAP) in South Africa (SA). OBJECTIVES. To summarise effective preventive strategies to reduce the burden of childhood CAP. METHODS. An expert subgroup reviewed existing SA guidelines and new publications focusing on prevention. Published evidence on pneumonia prevention informed the revisions;in the absence of evidence, expert opinion was used. Evidence was graded using the British Thoracic Society (BTS) grading system. RECOMMENDATIONS. General measures for prevention include minimising exposure to tobacco smoke or air pollution, breastfeeding, optimising nutrition, optimising maternal health from pregnancy onwards, adequate antenatal care and improvement in socioeconomic and living conditions. Prevention of viral transmission, including SARS-CoV-2, can be achieved by hand hygiene, environmental decontamination, use of masks and isolation of infected people. Specific preventive measures include vaccines as contained in the Expanded Programme on Immunisation schedule, isoniazid prophylaxis for tuberculosis, co-trimoxazole prophylaxis for HIV-infected infants and children who are immunosuppressed, and timely diagnosis of HIV, as well as antiretroviral therapy (ART) initiation. HIV-infected children treated with ART from early infancy, and HIV-exposed children, have similar immunogenicity and immune responses to most childhood vaccines as HIV-unexposed infants. VALIDATION. These recommendations are based on available published evidence supplemented by the consensus opinion of SA paediatric experts, and are consistent with those in published international guidelines.